Novo Nordisk

News

Novo hopes data will boost new insulin in US and Germany

Novo Nordisk hopes that new data supporting the cardiovascular and glycaemic safety of its Tresiba long-acting insulin will prove a game-changer in the US.

Views & Analysis

ADA preview: cardio data in diabetes, drug costs and healthc...

Invokana data could suggest cardio benefit for SGLT2 class.

Views & Analysis

Novo Nordisk: survival of the fittest applies in diabetes an...

Diabetes specialist Novo Nordisk is feeling the heat from increasingly price conscious US payers.

News

Novo hopes hypoglycaemia data will boost Tresiba

Lower severe hypo risk compared with Lantus - but no cardiac benefit.

News

AstraZeneca Amenities Building - Mississauga - Sept 2005
Non exclusive, unlimited time license for print & web to WZMH Architects

AZ’s Bydureon disappoints in diabetes outcomes trial

Results give advantage to Boehringer/Lilly's Jardiance.

News

Semaglutide could transform diabetes treatment, revive Novo ...

Oral formulation of GLP-1 drug could help cut heart attacks, tackle liver and kidney problems

Novo hopes data will boost new insulin in US and Germany

ADA preview: cardio data in diabetes, drug costs and healthc...

Novo Nordisk: survival of the fittest applies in diabetes an...

Novo hopes hypoglycaemia data will boost Tresiba

AZ’s Bydureon disappoints in diabetes outcomes trial

Semaglutide could transform diabetes treatment, revive Novo ...

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

Novo Nordisk

Editor's Picks